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Abstract 27 
Diabetes is the major cause of end stage renal disease globally, and novel treatments 28 
are urgently needed. Current therapeutic approaches for diabetic nephropathy are 29 
focusing on the inhibition of the renin angiotensin aldosterone system, on glycaemic 30 
and lipid control, and life style changes. In this review we will highlight new molecular 31 
insights in our understanding of the initiation and progression of diabetic nephropathy 32 
including glomerular insulin resistance, dysregulation of cellular substrate utilisation, 33 
podocyte-endothelial communication and inhibition of tubular sodium coupled glucose 34 
reabsorption. We believe these mechanisms offer new therapeutic targets that can be 35 
exploited to develop important renoprotective treatments for diabetic nephropathy over 36 
the next decade.  37 
  38 
 3 
INTRODUCTION 39 
Diabetes mellitus is a metabolic disorder associated with chronic micro- and 40 
macrovascular complications. One of the most feared chronic microvascular 41 
complications is diabetic nephropathy (DN), currently the leading cause of end-stage 42 
renal disease (ESRD) in the Western world. Strikingly, 40-45% of patients with type-1 43 
diabetes (T1D) develop DN and reach ESRD or die before its onset. Moreover, 44 
clinicians face a ~30% prevalence of patients with type-2 diabetes (T2D) and DN, with 45 
45% of patients currently on dialysis having a primary diagnosis of diabetes, a 46 
population also at high risk of developing cardiovascular disease [1]. 47 
 48 
An early sign of DN is an increased amount of urinary protein, manifested by 49 
“albuminuria”, which correlates with, and can predict, the progression of renal damage. 50 
Albuminuria arises from defects in the permeability of the glomerular filtration barrier 51 
consisting of glomerular endothelial cells (GECs) separated from specialized epithelia, 52 
called podocytes, by the glomerular basement membrane (GBM)[1]. Podocytes have 53 
extensive inter-digitating foot processes connected together by a slit diaphragm 54 
composed of proteins including nephrin and neph1, which interact with cytoplasmic 55 
adaptor and signalling proteins (PI3-Kinase, CD2AP, AKT, podocin). Nephrin is also 56 
linked with the podocyte actin cytoskeleton; the protein tyrosine kinase Fyn promotes 57 
nephrin phosphorylation which enhances its interaction with PI3-Kinase and PI3K-58 
dependent phosphorylation of AKT and subsequently increases Rac1 activity, leading 59 
to modification of the actin cytoskeleton with maintenance of a normal podocyte 60 
anatomical structure and function [2, 3]. The structure and integrity of the glomerulus 61 
is also maintained by a complex local autocrine/paracrine network between the 62 
podocyte and the GECs consisting of vascular growth factors and vasoactive peptides 63 
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which is disrupted in DN [4]. The GECs are highly fenestrated with a unique 64 
ultrastructure lacking fenestrae diaphragms which facilitate water and small solutes 65 
permeability [5]. GECs are covered by a glycocalyx consisting mainly of proteoglycans 66 
which include core proteins such as syndecan and attached glycosaminoglycan side 67 
chains which appear to be important in regulating the permeability of the glomerulus 68 
[6]. 69 
 70 
Animal and human studies have established that the metabolic and haemodynamic 71 
changes that occur in diabetes lead to ultrastructural alterations of the glomerular 72 
filtration barrier, including podocyte foot process fusion and detachment, GBM 73 
thickening, a reduced endothelial cell glycocalyx, mesangial extracellular matrix 74 
accumulation and glomerulosclerosis (Figure 1). These structural glomerular changes 75 
correlate with increasing albuminuria which has been proposed to be a marker of 76 
generalised systemic vascular dysfunction by the “Steno hypothesis” [7] and could 77 
represent a common pathogenetic mechanism for renal and extra-renal chronic 78 
vascular complications in diabetes [1]. 79 
 80 
Over the last 5-10 years our understanding of the molecular and cellular pathways by 81 
which diabetic kidney disease results in damage to the glomerular filtration barrier has 82 
increased. In this review, we will outline recent advances in glomerular insulin 83 
signalling, oxidative and endoplasmic reticulum (ER) stress and podocyte-endothelial 84 
communication that have revealed new exciting therapeutic directions for DN. 85 
 86 
 87 
Insulin resistance as a mechanism for the predisposition of DN 88 
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Insulin is a metabolic hormone which not only regulates glucose and the metabolism 89 
of other substrates but also directly modulates the biology of specific cells in a variety 90 
of tissues. In both T1D and T2D patients, the ability of insulin to elicit cellular responses 91 
is impaired, a concept termed “cellular insulin resistance”, and is associated with DN 92 
[8]. Insulin resistance correlates with the development of microalbuminuria both in T1D 93 
and T2D patients and patients with T1D are more likely to have a strong family history 94 
of insulin resistance when compared with those without kidney disease [9]. Insulin 95 
resistance has been implicated in the development of glomerular hypertension and 96 
hyperfiltration [10], seen in the initial phase of diabetic kidney disease [11]. 97 
Furthermore, in both T1D and T2D patients, insulin resistance per se contributes to 98 
higher salt sensitivity, which closely associates with increases in blood pressure, 99 
albuminuria, and a decline in renal function [12, 13]. 100 
 101 
Within the kidney many different cell types are insulin sensitive and express functional 102 
insulin receptors [14-17]. Furthermore, transgenic mouse models have revealed that 103 
inducing insulin resistance in different nephron compartments results in a variety of 104 
unfavourable renal phenotypes. In the glomerulus, approximately a decade ago it was 105 
discovered that human podocytes respond to insulin [14], and express the hallmark 106 
components of insulin sensitive cells including the insulin receptor, and key glucose 107 
transporters including GLUT4 and GLUT1. To elucidate the biological significance of 108 
insulin signalling in these cells, podocyte specific insulin receptor knockout mice were 109 
generated [18]. These animals developed albuminuria and a number of features of 110 
DN, including increased matrix production, glomerulosclerosis, and GBM thickening, 111 
but all in normoglycaemic conditions, suggesting that insulin resistance of this cell per 112 
se may be an important driver in glomerular diseases. Insulin signaling is important in 113 
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other parts of the nephron. Deletion of the insulin receptor In tubular epithelial cells 114 
widespread led to reduced natriuresis and hypertension [16]. Recent studies have 115 
begun to dissect out the precise function of the insulin receptor in specific tubular 116 
segments. These experiments revealed that loss of the insulin receptor in proximal 117 
tubules results in gluconeogenesis [19] while deletion in collecting ducts increased 118 
natriuresis and lowered blood pressure [20].  119 
 120 
 121 
Diabetes provides an ideal environment consisting of increased adiposity, 122 
hyperglycaemia, and inflammation which are all important players in promoting 123 
podocyte insulin resistance and glomerular dysfunction [17](Table 1). A recent study 124 
has identified SMAD3 within the inflammation/ fibrosis pathway as an important 125 
modulator of podocyte insulin sensitivity in a model of obesity related DN [21]. In this 126 
work, mice fed a high fat diet exhibited an increase in kidney and podocyte SMAD3 127 
expression levels which resulted in a severely fibrotic kidney; in these conditions 128 
SMAD3 knockout animals were protected from kidney damage and fibrosis. In parallel, 129 
fatty acid palmitate induces a SMAD3-mediated podocyte insulin resistance paralleled 130 
by mitochondrial dysfunction in vitro. These responses were exaggerated when 131 
animals became albuminuric, and could be rescued by SMAD3 blockade and 132 
restoration of podocyte insulin signalling [21]. Other studies have demonstrated that 133 
both Nucleotide-binding oligomerization domain containing protein 2 (NOD2)[22] and 134 
Toll-like receptor (TLR)[23] mediated-inflammation have an adverse effect on 135 
podocyte survival, insulin action, and glomerular permeability to protein. Decreased 136 
circulating adiponectin [24, 25], increased free fatty acids (FFA) levels  [26], and 137 
defects in insulin action promote glomerular cells and podocyte dysfunction, and 138 
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albuminuria [27, 28]. Epigenetic mechanisms may also be important in determining 139 
insulin resistance [29]. This concept has not been studied in great detail to-date, but 140 
Kumar and colleagues have shown that insulin resistance induced by palmitate in 141 
human urinary podocyte cell lines is associated with an increase in histone H3K36me2 142 
and reduced H3K27me3 on the promoter region of FOXO1, a regulator of 143 
gluconeogenic genes. This effect was long-lasting and persisted even after the 144 
normalisation of palmitate levels [30]. 145 
 146 
 147 
Glomerular insulin resistance, endoplasmic reticulum (ER) stress and 148 
autophagy in diabetic glomerulopathy 149 
There are many consequences of insulin resistance within glomeruli , which are likely 150 
to contribute to the progression of DN. One key mechanism is changes to the 151 
mitochondria and the closely connected ER [31]. Mitochondrial metabolic overload 152 
results in increased cellular oxidative stress and ER-stress which leads to the 153 
activation of unfolded protein response (UPR)[32]. UPR is a positive cellular response 154 
that in its early phase either refolds accumulated unfolded proteins, or degrades 155 
unfolded protein by the ubiquitin-proteasome pathway. Misfolded proteins are 156 
detected by the ER membrane stress sensors protein kinase RNA-like ER kinase 157 
(PERK), inositol-requiring protein 1α (IRE1α) and activating transcription factor 6α 158 
(ATF6α) and its activator X-box binding protein-1 (XBP-1), which, in turn, activates 159 
several signalling events and trigger a compensatory response to prevent further 160 
accumulation of misfolded protein. However, when the unfolded protein and cellular 161 
damage exceeds a threshold, chronic and unresolved stress results in a change from 162 
an adaptive to pro-apoptotic responses [32]. 163 
 8 
 164 
There is some evidence that glucose/oxidative stress-mediated ER stress plays a role 165 
in chronic vascular complications in DN [33]. Hyperglycemia, or increased glycation of 166 
proteins have been shown to mediate apoptosis partly through increases in ER stress 167 
in cultured murine podocytes [34, 35]. Activation of the UPR has also been observed 168 
in mouse glomerular mesangial cells exposed to glucose and glucosamine [36], and 169 
in kidneys from diabetic rats administered streptozotocin for 16 weeks [37]. Microarray 170 
analysis of human biopsies from patients with established DN showed that UPR genes 171 
were upregulated proportionally to the severity of diabetic renal lesions [38]. Finally, 172 
recent experimental evidence has demonstrated that pharmacological inhibition of ER 173 
stress and stabilization of the UPR is beneficial in diabetic glomerulopathy [39]. 174 
 175 
Two studies have used transgenic mice to link podocyte insulin resistance with 176 
mitochondrial function and ER stress. Ising and colleagues generated a mouse model 177 
of podocyte mitochondrial dysfunction by specifically knocking out a key molecule in 178 
this cell involved in mitochondrial fusion called prohibitin-2 [40]. This caused a severe 179 
phenotype including glomerulosclerosis, renal failure and death at approximately a 180 
month of age. They then went on to inhibit both the insulin receptor and IGF-1 receptor 181 
(IGF1R) contemporaneously with podocyte-specific knockdown of prohibitin-2. 182 
Inhibiting the insulin receptor alone, or in combination with the IGF1R was partially 183 
protective and resulted in a significantly longer life span of the mice [40]. This suggests 184 
that insulin resistance could reflect a “protective” resetting of cellular substrate 185 
utilisation to shield from excess substrate flow to mitochondria with “impaired” 186 
respiratory capabilities. In another study, Madhusudhan et al. have elegantly shown 187 
that under diabetic conditions ER adaptive mechanisms are impaired in the podocyte 188 
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and that this is exacerbated when the cell is rendered more insulin resistant. Studying 189 
human and murine DN they discovered that nephropathy was associated with 190 
alterations in the UPR with impairment of the nuclear translocation of XBP-1. Genetic 191 
ablation of the transcription factor XBP-1 or activation of ATF6 (downstream of XBP-192 
1) in the podocyte of diabetic mice aggravates DN. Of interest, mice with genetically 193 
impaired podocyte insulin signalling exhibited impaired UPR (XBP-1 activation) that 194 
was associated with more severe diabetic kidney disease when compared with 195 
diabetic controls [41]. 196 
 197 
Autophagy, regulated by the mammalian target of rapamycin complex 1 (mTORC1) 198 
is, with the UPR, essential to maintain cellular homeostasis and in the context of ER 199 
stress contributes towards the elimination of toxic and damaged cellular components 200 
[42]. Haploinsufficiency of mTORC1 in podocytes or administration of rapamycin (a 201 
mTORC1 inhibitor) resulting in activation of autophagy [43], has been shown to 202 
prevent progressive DN [44, 45]. In contrast, mTORC1 activation in podocytes, 203 
resulting in inhibition of autophagy, leads to accelerated DN [46]. Loss of insulin 204 
sensitivity in cultured podocytes results in suppression of autophagy and addition of 205 
rapamycin in these cells attenuates insulin resistance [47]. 206 
 207 
 208 
Insulin resistance, the glomerular cell cytoskeleton and other mechanisms 209 
Experiments using podocyte cell lines have begun to reveal other downstream targets 210 
of insulin resistance which may play a role in DN. Addition of exogenous insulin to 211 
human podocytes in culture led to cytoskeletal rearrangement [18], a process which 212 
has been pharmacologically targeted using small molecules as a novel therapy for DN 213 
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[48]. Other studies [49] have identified the cytoskeleton protein septin-7 as playing an 214 
important role in the regulation of insulin-mediated translocation of GLUT4 vesicles to 215 
the plasma membrane and the control of podocyte glucose transport. Insulin may also 216 
modulate calcium signalling in podocytes which has been shown to be important in 217 
maintaining cytoskeletal dynamics by altering the expression of canonical transient 218 
receptor potential-6 channel-TRPC6 [50] and large-conductance Ca(2+)-activated 219 
K(+) channels [51].  220 
 221 
Insulin stimulates the Phosphoinositide 3-kinase (PI3K) pathway and causes AKT 222 
activation. In normal physiology, insulin stimulation of podocytes results in AKT 223 
phosphorylation (activation), while, in insulin-resistant disease settings such as 224 
diabetes, a number of reports have shown an early loss of glomerular AKT 225 
phosphorylation whilst AKT signaling is maintained in the tubular compartment of the 226 
kidney [28].  AKT exists in three isoforms with AKT2 being located specifically in the 227 
podocyte within the kidney [52]. A loss of podocyte AKT2 activation is detrimental 228 
when there is chronic kidney disease associated with nephron loss [52]. AKT2 is the 229 
major isoform through which insulin signals [53]. It is currently not completely clear if 230 
the loss of renal AKT activation is detrimental in the setting of diabetes as a number 231 
of studies have shown an increase in AKT phosphorylation in the vasculature in 232 
experimental animal models of diabetes [54-58], and pharmacological inhibition of the 233 
AKT activation by AS101, may confer renoprotection in diabetes [59]. More work will 234 
have to be performed to dissect the exact role of AKT in diabetic kidney disease. 235 
 236 
Insulin can also modulate the renin-angiotensin-aldosterone system, critical for 237 
regulating glomerular haemodynamics in DN, by increasing the expression and activity 238 
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of angiotensin converting enzyme-2 (ACE2)[60]. Further work is required to identify 239 
other downstream targets of podocyte insulin signalling ideally using systems biology 240 
genomic and proteomic approaches. Candidate molecules altered by insulin signalling 241 
might include recently identified genes found to be associated with the early stages of 242 
albuminuria in in-bred strains of mice [61]. 243 
 244 
 245 
Reactive oxygen species and diabetic nephropathy 246 
Over the last decade, an attractive unifying hypothesis has been put forward to explain 247 
diabetic microvascular complications; specifically it was postulated that an excess in 248 
cellular substrate availability leads to an increase in reactive oxygen species (ROS) 249 
which in turn drives vascular complications in DN [62]. However, this unifying 250 
hypothesis has been challenged by the negative results of antioxidant-based clinical 251 
trials [63], and a new theory of “mitochondrial hormesis” has been proposed [64], 252 
whereby the increased mitochondrial superoxide production is considered an indicator 253 
of healthy mitochondria and physiologic oxidative phosphorylation. 254 
 255 
Recent research has found a reduction of superoxide in the kidneys of streptozotocin 256 
(STZ)-induced diabetic Akita-mice, as assessed by a combination of in vivo real-time 257 
transcutaneous fluorescence, confocal microscopy, and electron paramagnetic 258 
resonance analysis [65]. The authors of this study found that chronic exposure to high 259 
glucose levels (as occurs in diabetes) results in disrupted mitochondria, which was 260 
associated with a reduced respiration and a lowering in mitochondrial superoxide. 261 
Interestingly, genetic or pharmacological correction of mitochondrial dysfunction by 262 
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improving substrate utilisation was recently found to be renoprotective in a mouse 263 
model of tubulointerstitial fibrosis [66].  264 
 265 
From experimental animal studies it appears that increased cytosolic superoxide and 266 
other non-mitochondrial sources of ROS generation play a prominent role in diabetic 267 
kidney disease and that strategies involving a more targeted (towards specific cellular 268 
compartments such as the cytosol) antioxidant approach, may be important to optimize 269 
renoprotection in diabetes [67]. Along these lines, human studies have shown that 270 
leukocytes obtained from patients with diabetes and DN (when compared with non-271 
diabetics or patients with diabetes without DN) have a reduced maximal respiration 272 
and reserve capacity [68, 69] suggesting that chronic metabolic stress in the presence 273 
of a reduced mitochondrial function (being this primary or secondary) will manifest with 274 
low ATP-linked respiration, low reserve capacity and reduced mitochondrial ROS 275 
generation. 276 
 277 
It could be speculated that metabolic stress could initially (early phase) promote an 278 
excess production of mitochondrial superoxide [62] that will lead, in a subsequent 279 
chronic phase (late phase), towards mitochondrial damage, progressive deterioration 280 
in bioenergetic cellular function, reduced ATP synthesis and cell death. Future work 281 
will address these questions, and need to evaluate whether cells are able to maintain 282 
adequate number of healthy mitochondria which can then burn sufficient substrates for 283 
energy production and maintain a “balanced” level of ROS (Figure 2). 284 
 285 
AMP-activated protein kinase (AMPK) is a stress-activated kinase that is activated in 286 
response to depleting ATP to preserve cell survival under conditions of reduced 287 
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substrate utilisation. AMPK activation has been involved in mitochondrial biogenesis 288 
by leading to increased mitochondrial substrate utilisation and ATP generation, in 289 
parallel with stimulation of antioxidant gene expression to ensure an optimal redox 290 
balance [70]. Reduced AMPK, as seen in the diabetic kidney of both rodents and 291 
humans [65], is associated with reduced catabolic activity (mitochondrial function) [65], 292 
and reduced AMPK-mediated inhibition of NADPH oxidase (Nox2) resulting in 293 
increased ROS production [71, 72]. Taken together, these results suggest that, in the 294 
diabetic kidney, upregulation of AMPK could be therapeutically beneficial in DN [73] to 295 
regulate nutrient utilisation and mitochondrial function towards maintenance of an 296 
optimum redox balance. 297 
 298 
Overall, more work is required in the DN field to dissect between these opposing 299 
theories specifically by examining mitochondrial function and specific ROS moieties 300 
both in vitro and in tissues. 301 
 302 
 303 
Vascular endothelial growth factor-A (VEGFA) and the glycocalyx 304 
Recent studies have shown a connection between insulin resistance and the 305 
subsequent production of VEGFA in podocytes [74]. This finding is likely to be 306 
important in the setting of DN with many elegant studies using transgenic mice 307 
highlighting the importance of podocyte VEGFA levels in the progression of this 308 
condition [4]. A new aspect of VEGFA signalling in the glomerulus is potential cross 309 
talk between VEGFA secreted from podocytes and the GECs glycocalyx in the setting 310 
of diabetes. There is clear evidence that the GECs glycocalyx is lost both systemically 311 
and within the diabetic glomerulus, and that this contributes to both cardiovascular and 312 
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renal complications [6]. Mechanistically there are a number of pathways which led to 313 
loss of the glomerular glycocalyx including hyperglycaemia [75], and ROS [76].  314 
 315 
During the early phases of diabetes an increase in VEGFA causes glycocalyx 316 
shedding from the GECs. Furthermore, the inhibitory isoform of VEGFA called VEGF-317 
A165b also plays a role in maintaining the GECs glycocalyx in diabetes. Oltean et al. 318 
[77] have shown that in diabetic patients with progressive nephropathy, the renal 319 
expression of VEGF-A165b is lost. They went on to develop a number of murine models 320 
of DN and have shown that genetic overexpression or pharmacological administration 321 
of VEGF-A165b to the mouse, acting through VEGF receptor 2 in the GECs, restores 322 
damaged glomerular endothelial glycocalyx and improves renal function. VEGF-A165b 323 
also improved the permeability of isolated human diabetic glomeruli suggesting the 324 
response is conserved across murine and human species [77]. 325 
 326 
VEGFA signalling is only one component of a complex system of molecular cross talk 327 
between the podocyte and glycocalyx. New insights have revealed that molecules 328 
produced by the endothelium can signal to the podocyte and then back to the 329 
glomerular glycocalyx. Using transgenic murine models and conditionally immortalised 330 
murine podocytes and GECs, Garsen et al have shown that endothelin-1 (ET-1), an 331 
endothelial derived vasoconstrictor, is released by the GECs in diabetic conditions and 332 
leads to shedding of the glycocalyx [78]. This is prevented by deleting the ET-1 333 
receptor specifically in the podocyte. This is therapeutically intriguing as there are ET-334 
1 receptor antagonists that have been shown to ameliorate early microalbuminuric 335 
diabetic kidney disease [79]. In the future, therapeutic approaches to maintain the 336 
GECs glycocalyx should be explored in more detail (Figure 3). 337 
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 339 
SGLT2 and kidney disease 340 
Poor glycaemic control and hyperinsulinaemia (at least in the early phase of diabetes) 341 
lead to upregulation of SGLT2 expression and proximal tubular SGLT2-mediated 342 
sodium-glucose reabsorption [80], which in turns is believed to also contribute to higher 343 
blood pressure levels [81]. SGLT2 inhibitors have recently been developed as oral 344 
hypoglycaemic agents [82]. The SGLT2 antagonists block the sodium-coupled energy 345 
dependent glucose proximal tubular reabsorption resulting in improvement in diabetes 346 
control, weight loss and blood pressure lowering. Recent clinical trials have 347 
demonstrated a dramatic cardiovascular [83] and renoprotective [84] effect of the 348 
SGLT2 inhibitor empaglifozin. 349 
The mechanism by which SGLT2 inhibitors exert their renoprotective effects is 350 
currently unknown. One possibility is that the improvement in renal disease is 351 
secondary to activation of tubuloglomerular feedback, a prime mechanism that 352 
determines a reduction in glomerular capillary pressure [85]. A complementary 353 
mechanism may be that the inhibition of enhanced tubuli sodium-coupled glucose 354 
transport seen in diabetes would result in diminished tubulointerstitial injury and 355 
progression of DN [81]. The use of SGLT2 inhibitors in combination with inhibitors of 356 
the renin-angiotensin-aldosterone system in patients with diabetes may confer some 357 
renoprotection via upregulation of ACE2 and angiotensin 1-7/ 1-9 [86] which retains a 358 
vasodilatory, anti-proliferative, anti-inflammatory and anti-oxidative stress effect [87].  359 
Inhibition of SGLT2 increased expression and activity in diabetes [85] could lead to 360 
restriction of chronic excess in substrates (glucose) availability, known to result in 361 
AMPK inhibition [88], and promote a favourable renal outcome. Studies wll have to 362 
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dissect whether inhibition of SGLT2 could result in AMPK activation and secondary 363 
renoprotection.  364 
In parallel to these “renal mechanisms”, natriuresis and plasma volume contraction 365 
paralleled by blood pressure reduction has been also been proposed as a “systemic” 366 
renoprotective mechanisms for SGLT2 inhibitors [89](Figure 4). 367 
 368 
Concluding Remarks and Future Perspectives  369 
Glomerular cellular insulin resistance plays an important role in mitochondrial 370 
dysfunction-ER stress and the UPR, which contribute to glomerular cell dysfunction 371 
and progressive kidney disease. AMPK, with its important role in mitochondrial 372 
function, could represent a potential target for treatment in DN; more studies are 373 
required to assess the role of AMPK on podocyte biology and the regulation of the 374 
glomerular filtration barrier. A link between the tubular compartment and the 375 
glomerulus is evident in the pathophysiology of tubular SGLT2-mediated Na-coupled 376 
glucose reabsorption in diabetes, however it is not yet completely clear what are the 377 
mechanisms underlying these beneficial effects. Future studies will need to better 378 
dissect the cellular mechanisms underlying the proposed pathways outlined in this 379 
article, specifically focusing on the physiology of the nephron as a whole entity, and 380 
by identifying potentially targetable molecules for future treatment.   381 
 382 
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TABLE 1  397 
Diabetes results in inflammation, increased adiposity and chronic hyperglycaemia 398 
which drive podocyte insulin resistance resulting in disruption to podocytes and the 399 
glomerulus.  (NOD2: Nucleotide-binding oligomerization domain containing protein 2, 400 
TLR: Toll-like receptor, SMAD: vertebrate homologues of Sma and Mad; FFAs: free 401 
fatty acids; SHP-1: Src homology-2 domain-containing phos- phatase-1) 402 
 403 
Diabetes related 
phenotypes 
Molecular 
mechanisms 
Glomerular phenotype REF # 
Chronic 
inflammation 
Increased NOD2 
Increased pro-
inflammatory responses 
and impaired insulin 
signaling 
 [22] 
Increased TLR 
Podocyte inflammation 
and insulin resistance  
  [23] 
Increased SMAD 
Mitochondrial 
dysfunction and insulin 
resistance in podocytes 
    [21] 
Obesity 
Decreased 
adiponectin 
Albuminuria and 
increased oxidative 
stress in podocytes 
    [24] 
Increased FFAs 
Inhibition of insulin-
stimulated glucose 
uptake in human 
podocytes 
    [26] 
Elevated blood 
sugar 
Increased SHP-1 
Podocyte insulin 
resistance and 
detachment 
     [27] 
Ubiquitination and 
degradation of 
components of insulin 
signaling pathway  
Diabetic glomerulopathy 
and albuminuria 
     [28] 
 404 
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Figure legends: 405 
 406 
 407 
 408 
 409 
Figure 1: Schematic structure of a normal and diabetic glomeruli.  410 
(A) Schematic representation of a normal glomerular structure. (B) The major 411 
glomerular structural changes occurring in diabetic glomerulopathy. Note the 412 
extensive mesangial expansion, the thickening of the glomerular basement membrane 413 
(GBM), the detachment of podocyte, and the impairment in the glycocalyx and 414 
glomerular endothelial cells (GECs). 415 
  416 
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 417 
 418 
Figure 2: Hypothetical shift of superoxide level imbalance in diabetic 419 
complications. 420 
Acute (early phase) exposure of cells to elevated glucose levels results in upregulation 421 
of glucose oxidation with pyruvate-mediated stimulation of the tricarboxylic acid (TCA) 422 
cycle with increased production of electron donors (NADH, FADH2) that, via the 423 
electron transport chain, will results in an excess generation of superoxide (O2-). Cells 424 
chronically exposed to elevated glucose levels (late phase) will result in reduction in 425 
the availability of acetyl-CoA (secondary to inhibition of pyruvate dehydrogenase 426 
activity) for the mitochondria resulting in reduced electron transport chain activity, a 427 
fall in mitochondrial ATP production, less mitochondria superoxide production and 428 
cellular dysfunction. 429 
 430 
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 431 
 432 
 433 
Figure 3: Glomerular cell cross-talk and glycocalyx.  434 
Transmission electron microscopy image of the glomerular filtration barrier (podocyte 435 
glomerular basement membrane (GBM), glomerular endothelial cells (GEC), and 436 
glycocalyx) highlighting how molecules produced by the podocytes and endothelium 437 
(via the podocyte) can signal to the glomerular glycocalyx. Recently identified key 438 
molecules such as VEGF-A165b, VEGF-C, and angiopoietin-1 (ANGPT1) confer a 439 
beneficial effect (green arrows) towards glycocalyx maintenance. Conversely VEGF-440 
A165 and Endothelin (secreted by GECs and signals to the Endothelin-1 receptor in the 441 
podocyte causing this cell to release heparanase, which then acts on the glomerular 442 
glycocalyx to cleave heparin sulphate) promote shedding of the GECs glycocalyx (red 443 
arrows).  444 
Podocyte 
GBM
GECs
Glycocalyx
VEGF-A165
VEGF-A165b
VEGF-C
ANGPT1
Glycocalyx
shedding
Glycocalyx
restoration
1. Endothelin
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 448 
Figure 4: Proposed SGLT2 inhibition-mediated renoprotective mechanisms. 449 
SGLT2 inhibition blocks sodium-glucose coupled glucose reabsorption at the S1 S2 450 
segment of the proximal tubule. The net result is loss of glucose and sodium (the latter 451 
especially in patients on renin angiotensin aldosterone blockade) in the urine, with 452 
secondary weight loss, improvement in glycaemic control, blood pressure fall, and 453 
plasma volume contraction. These effects confer cardiac and renal protection in 454 
patients with diabetes. (ACE2: angiotensin converting enzyme 2) 455 
  456 
SGLT2 
inhibition
glycosuria
natriuresis
weight loss
↓blood pressure
↓plasma volume
↑tubulo
glomerular feedback
↓HbA1c
↑uricosuria
activation of ACE2 -
↑angiotensin 1-9/1-7
↓inflammation
↓glucose toxicity
↓intraglomerular
pressure
↓hyperfiltration
Renoprotection
 23 
References: 457 
1 Gnudi, L., Gentile, G., Ruggenenti, P. (2016) The patient with diabetes mellitus. In 458 
Oxford Textbook of Clinical Nephrology (Turner, N., Lamiere, N., Goldsmith, 459 
D.J.,Wineearls, C.G., Himmelfarb, J., Remuzzi, G., ed), pp. 1199-1247, Oxford 460 
University Press 461 
2 Benzing, T. (2004) Signaling at the slit diaphragm. J Am Soc Nephrol 15, 1382-1391 462 
3 Zhu, J., et al. (2008) Nephrin mediates actin reorganization via phosphoinositide 3-463 
kinase in podocytes. Kidney Int 73, 556-566 464 
4 Gnudi, L., et al. (2015) Vascular growth factors play critical roles in kidney glomeruli . 465 
Clin Sci (Lond) 129, 1225-1236 466 
5 Haraldsson, B., et al. (2008) Properties of the glomerular barrier and mechanisms 467 
of proteinuria. Physiol Rev. 88, 451-487 468 
6 Salmon, A.H., et al. (2012) Loss of the endothelial glycocalyx links albuminuria and 469 
vascular dysfunction. J Am Soc Nephrol 23, 1339-1350 470 
7 Deckert, T., et al. (1989) Albuminuria reflects widespread vascular damage. The 471 
Steno hypothesis. Diabetologia 32, 219-226 472 
8 Orchard, T.J., et al. (2002) Nephropathy in type 1 diabetes: a manifestation of insulin 473 
resistance and multiple genetic susceptibilities? Further evidence from the Pittsburgh 474 
Epidemiology of Diabetes Complication Study. Kidney Int 62, 963-970 475 
9 Karalliedde, J. and Gnudi, L. (2016) Diabetes mellitus, a complex and 476 
heterogeneous disease, and the role of insulin resistance as a determinant of diabetic 477 
kidney disease. Nephrol Dial Transplant 31, 206-213 478 
 24 
10 Sasson, A.N. and Cherney, D.Z. (2012) Renal hyperfiltration related to diabetes 479 
mellitus and obesity in human disease. World J Diabetes 3, 1-6 480 
11 Gnudi, L., et al. (2007) Mechanical forces in diabetic kidney disease: a trigger for 481 
impaired glucose metabolism. J.Am.Soc.Nephrol. 18, 2226-2232 482 
12 Trevisan, R., et al. (1998) Enhanced responsiveness of blood pressure to sodium 483 
intake and to angiotensin II is associated with insulin resistance in IDDM patients with 484 
microalbuminuria. Diabetes 47, 1347-1353 485 
13 Vedovato, M., et al. (2004) Effect of sodium intake on blood pressure and 486 
albuminuria in Type 2 diabetic patients: the role of insulin resistance. Diabetologia 47, 487 
300-303 488 
14 Coward, R.J., et al. (2005) The human glomerular podocyte is a novel target for 489 
insulin action. Diabetes 54, 3095-3102 490 
15 Butlen, D., et al. (1988) Insulin receptors along the rat nephron: [125I] insulin 491 
binding in microdissected glomeruli and tubules. Pflugers Arch 412, 604-612 492 
16 Tiwari, S., et al. (2008) Impaired sodium excretion and increased blood pressure in 493 
mice with targeted deletion of renal epithelial insulin receptor. Proc Natl Acad Sci U S 494 
A 105, 6469-6474 495 
17 Lay, A. and Coward, R.J. (2014) Recent advances in our understanding of insulin 496 
signalling to the podocyte. Nephrol Dial Transplant 29, 1127-1133 497 
18 Welsh, G.I., et al. (2010) Insulin signaling to the glomerular podocyte is critical for 498 
normal kidney function. Cell Metab 12, 329-340 499 
19 Tiwari, S., et al. (2013) Deletion of the insulin receptor in the proximal tubule 500 
promotes hyperglycemia. J Am Soc Nephrol 24, 1209-1214 501 
 25 
20 Li, L., et al. (2013) Reduced ENaC activity and blood pressure in mice with genetic 502 
knockout of the insulin receptor in the renal collecting duct. Am J Physiol Renal Physiol 503 
304, F279-288 504 
21 Sun, Y.B., et al. (2015) Smad3 deficiency protects mice from obesity-induced 505 
podocyte injury that precedes insulin resistance. Kidney Int 88, 286-298 506 
22 Du, P., et al. (2013) NOD2 promotes renal injury by exacerbating inflammation and 507 
podocyte insulin resistance in diabetic nephropathy. Kidney Int 84, 265-276 508 
23 Cha, J.J., et al. (2013) Renal protective effects of toll-like receptor 4 signaling 509 
blockade in type 2 diabetic mice. Endocrinology 154, 2144-2155 510 
24 Sharma, K., et al. (2008) Adiponectin regulates albuminuria and podocyte function 511 
in mice. J Clin.Invest 118, 1645-1656 512 
25 Sweiss, N. and Sharma, K. (2014) Adiponectin effects on the kidney. Best Pract 513 
Res Clin Endocrinol Metab 28, 71-79 514 
26 Lennon, R., et al. (2009) Saturated fatty acids induce insulin resistance in human 515 
podocytes: implications for diabetic nephropathy. Nephrol Dial Transplant 24, 3288-516 
3296 517 
27 Drapeau, N., et al. (2013) Expression of SHP-1 induced by hyperglycemia prevents 518 
insulin actions in podocytes. Am J Physiol Endocrinol Metab 304, E1188-1198 519 
28 Mima, A., et al. (2011) Glomerular-specific protein kinase C-beta-induced insulin 520 
receptor substrate-1 dysfunction and insulin resistance in rat models of diabetes and 521 
obesity. Kidney Int 79, 883-896 522 
29 Duque-Guimaraes, D.E. and Ozanne, S.E. (2013) Nutritional programming of 523 
insulin resistance: causes and consequences. Trends Endocrinol Metab 24, 525-535 524 
 26 
30 Kumar, S., et al. (2016) Fatty acid induced metabolic memory involves alterations 525 
in renal histone H3K36me2 and H3K27me3. Mol Cell Endocrinol 422, 233-242 526 
31 Kornmann, B., et al. (2009) An ER-mitochondria tethering complex revealed by a 527 
synthetic biology screen. Science 325, 477-481 528 
32 Hetz, C. (2012) The unfolded protein response: controlling cell fate decisions under 529 
ER stress and beyond. Nature reviews. Molecular cell biology 13, 89-102 530 
33 Zhuang, A. and Forbes, J.M. (2014) Stress in the kidney is the road to pERdition: 531 
is endoplasmic reticulum stress a pathogenic mediator of diabetic nephropathy? The 532 
Journal of endocrinology 222, R97-111 533 
34 Cao, Y., et al. (2014) Role of endoplasmic reticulum stress in apoptosis of 534 
differentiated mouse podocytes induced by high glucose. Int J Mol Med 33, 809-816 535 
35 Chen, Y., et al. (2008) Effect of taurine-conjugated ursodeoxycholic acid on 536 
endoplasmic reticulum stress and apoptosis induced by advanced glycation end 537 
products in cultured mouse podocytes. Am J Nephrol 28, 1014-1022 538 
36 Cheng, D.W., et al. (2006) An analysis of high glucose and glucosamine-induced 539 
gene expression and oxidative stress in renal mesangial cells. Arch Physiol Biochem 540 
112, 189-218 541 
37 Liu, G., et al. (2008) Apoptosis induced by endoplasmic reticulum stress involved 542 
in diabetic kidney disease. Biochem Biophys Res Commun 370, 651-656 543 
38 Lindenmeyer, M.T., et al. (2008) Proteinuria and hyperglycemia induce 544 
endoplasmic reticulum stress. J Am Soc Nephrol 19, 2225-2236 545 
 27 
39 Cao, A.L., et al. (2016) Ursodeoxycholic acid and 4-phenylbutyrate prevent 546 
endoplasmic reticulum stress-induced podocyte apoptosis in diabetic nephropathy. 547 
Lab Invest  548 
40 Ising, C., et al. (2015) Inhibition of insulin/IGF-1 receptor signaling protects from 549 
mitochondria-mediated kidney failure. EMBO Mol Med 7, 275-287 550 
41 Madhusudhan, T., et al. (2015) Defective podocyte insulin signalling through p85-551 
XBP1 promotes ATF6-dependent maladaptive ER-stress response in diabetic 552 
nephropathy. Nature communications 6, 6496 553 
42 Kroemer, G., et al. (2010) Autophagy and the integrated stress response. Mol Cell 554 
40, 280-293 555 
43 Kim, J., et al. (2011) AMPK and mTOR regulate autophagy through direct 556 
phosphorylation of Ulk1. Nat Cell Biol 13, 132-141 557 
44 Godel, M., et al. (2011) Role of mTOR in podocyte function and diabetic 558 
nephropathy in humans and mice. J Clin Invest 121, 2197-2209 559 
45 Xiao, T., et al. (2014) Rapamycin promotes podocyte autophagy and ameliorates  560 
renal injury in diabetic mice. Mol Cell Biochem 394, 145-154 561 
46 Inoki, K., et al. (2011) mTORC1 activation in podocytes is a critical step in the 562 
development of diabetic nephropathy in mice. J Clin Invest 121, 2181-2196 563 
47 Xu, Y., et al. (2016) Autophagy downregulation contributes to insulin resistance 564 
mediated injury in insulin receptor knockout podocytes in vitro. PeerJ 4, e1888 565 
48 Schiffer, M., et al. (2015) Pharmacological targeting of actin-dependent dynamin 566 
oligomerization ameliorates chronic kidney disease in diverse animal models. Nat Med 567 
21, 601-609 568 
 28 
49 Wasik, A.A., et al. (2012) Septin 7 forms a complex with CD2AP and nephrin and 569 
regulates glucose transporter trafficking. Mol Biol Cell 23, 3370-3379 570 
50 Kim, E.Y., et al. (2012) Insulin increases surface expression of TRPC6 channels in 571 
podocytes: role of NADPH oxidases and reactive oxygen species. Am J Physiol Renal 572 
Physiol 302, F298-307 573 
51 Kim, E.Y. and Dryer, S.E. (2011) Effects of insulin and high glucose on mobilization 574 
of slo1 BKCa channels in podocytes. J Cell Physiol 226, 2307-2315 575 
52 Canaud, G., et al. (2013) AKT2 is essential to maintain podocyte viability and 576 
function during chronic kidney disease. Nat Med 19, 1288-1296 577 
53 George, S., et al. (2004) A family with severe insulin resistance and diabetes due 578 
to a mutation in AKT2. Science 304, 1325-1328 579 
54 Zdychova, J. and Komers, R. (2005) Emerging role of Akt kinase/protein kinase B 580 
signaling in pathophysiology of diabetes and its complications. Physiol Res 54, 1-16 581 
55 Wu, D., et al. (2009) PKC-beta1 mediates glucose-induced Akt activation and TGF-582 
beta1 upregulation in mesangial cells. J Am Soc Nephrol 20, 554-566 583 
56 Kato, M., et al. (2006) Role of the Akt/FoxO3a pathway in TGF-beta1-mediated 584 
mesangial cell dysfunction: a novel mechanism related to diabetic kidney disease. J 585 
Am Soc Nephrol 17, 3325-3335 586 
57 Xin, X., et al. (2005) Glucose-induced Akt1 activation mediates fibronectin 587 
synthesis in endothelial cells. Diabetologia 48, 2428-2436 588 
58 Kim, S.Y., et al. (2009) Role of kidney ADP-ribosyl cyclase in diabetic nephropathy. 589 
Am J Physiol Renal Physiol 296, F291-297 590 
 29 
59 Shemesh, II, et al. (2014) AS101 prevents diabetic nephropathy progression and 591 
mesangial cell dysfunction: regulation of the AKT downstream pathway. PLoS One 9, 592 
e114287 593 
60 Riera, M., et al. (2014) Effect of insulin on ACE2 activity and kidney function in the 594 
non-obese diabetic mouse. PLoS One 9, e84683 595 
61 Long, D.A., et al. (2013) Albuminuria is associated with too few glomeruli and too 596 
much testosterone. Kidney Int  597 
62 Brownlee, M. (2001) Biochemistry and molecular cell biology of diabetic 598 
complications. Nature 414, 813-820 599 
63 Forbes, J.M., et al. (2008) Oxidative stress as a major culprit in kidney disease in 600 
diabetes. Diabetes 57, 1446-1454 601 
64 Sharma, K. (2015) Mitochondrial hormesis and diabetic complications. Diabetes 602 
64, 663-672 603 
65 Dugan, L.L., et al. (2013) AMPK dysregulation promotes diabetes-related reduction 604 
of superoxide and mitochondrial function. J Clin Invest 123, 4888-4899 605 
66 Kang, H.M., et al. (2015) Defective fatty acid oxidation in renal tubular epithelial 606 
cells has a key role in kidney fibrosis development. Nat Med 21, 37-46 607 
67 Forbes, J.M. and Cooper, M.E. (2013) Mechanisms of diabetic complications. 608 
Physiological reviews 93, 137-188 609 
68 Czajka, A., et al. (2015) Altered Mitochondrial Function, Mitochondrial DNA and 610 
Reduced Metabolic Flexibility in Patients With Diabetic Nephropathy. EBioMedicine 2, 611 
499-512 612 
 30 
69 Chacko, B.K., et al. (2015) The Bioenergetic Health Index is a sensitive measure 613 
of oxidative stress in human monocytes. Redox biology 8, 43-50 614 
70 Hardie, D.G., et al. (2012) AMPK: a nutrient and energy sensor that maintains 615 
energy homeostasis. Nature reviews. Molecular cell biology 13, 251-262 616 
71 Sedeek, M., et al. (2010) Critical role of Nox4-based NADPH oxidase in glucose-617 
induced oxidative stress in the kidney: implications in type 2 diabetic nephropathy. Am 618 
J Physiol Renal Physiol 299, F1348-1358 619 
72 Eid, A.A., et al. (2010) AMP-activated protein kinase (AMPK) negatively regulates 620 
Nox4-dependent activation of p53 and epithelial cell apoptosis in diabetes. J Biol 621 
Chem 285, 37503-37512 622 
73 Al-Rasheed, N.M., et al. (2015) Renoprotective Effects of Fenofibrate via 623 
Modulation of LKB1/AMPK mRNA Expression and Endothelial Dysfunction in a Rat 624 
Model of Diabetic Nephropathy. Pharmacology 95, 229-239 625 
74 Hale, L.J., et al. (2013) Insulin directly stimulates VEGF-A production in the 626 
glomerular podocyte. Am J Physiol Renal Physiol 305, F182-188 627 
75 Singh, A., et al. (2011) High glucose causes dysfunction of the human glomerular 628 
endothelial glycocalyx. Am J Physiol Renal Physiol 300, F40-48 629 
76 Singh, A., et al. (2013) Reactive oxygen species modulate the barrier function of 630 
the human glomerular endothelial glycocalyx. PLoS One 8, e55852 631 
77 Oltean, S., et al. (2014) Vascular Endothelial Growth Factor-A165b Is Protective 632 
and Restores Endothelial Glycocalyx in Diabetic Nephropathy. J Am Soc Nephrol  633 
78 Garsen, M., et al. (2016) Endothelin-1 Induces Proteinuria by Heparanase-634 
Mediated Disruption of the Glomerular Glycocalyx. J Am Soc Nephrol  635 
 31 
79 de Zeeuw, D., et al. (2014) The endothelin antagonist atrasentan lowers residual 636 
albuminuria in patients with type 2 diabetic nephropathy. J Am Soc Nephrol 25, 1083-637 
1093 638 
80 Rahmoune, H., et al. (2005) Glucose transporters in human renal proximal tubular 639 
cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 640 
54, 3427-3434 641 
81 Vallon, V. and Thomson, S.C. (2012) Renal function in diabetic disease models: 642 
the tubular system in the pathophysiology of the diabetic kidney. Annual review of 643 
physiology 74, 351-375 644 
82 Ferrannini, E. and Solini, A. (2012) SGLT2 inhibition in diabetes mellitus: rationale 645 
and clinical prospects. Nat Rev Endocrinol 8, 495-502 646 
83 Zinman, B., et al. (2015) Empagliflozin, Cardiovascular Outcomes, and Mortality in 647 
Type 2 Diabetes. N Engl J Med 373, 2117-2128 648 
84 Wanner, C., et al. (2016) Empagliflozin and Progression of Kidney Disease in Type 649 
2 Diabetes. N Engl J Med  650 
85 Vallon, V. (2015) The mechanisms and therapeutic potential of SGLT2 inhibitors in 651 
diabetes mellitus. Annu Rev Med 66, 255-270 652 
86 Tikellis, C., et al. (2008) ACE2 deficiency modifies renoprotection afforded by ACE 653 
inhibition in experimental diabetes. Diabetes 57, 1018-1025 654 
87 Burrell, L.M., et al. (2004) ACE2, a new regulator of the renin-angiotensin system. 655 
Trends Endocrinol Metab 15, 166-169 656 
88 Viollet, B., et al. (2010) AMPK inhibition in health and disease. Crit Rev Biochem 657 
Mol Biol 45, 276-295 658 
 32 
89 Rajasekeran, H., et al. (2016) Sodium-glucose cotransporter 2 inhibition and 659 
cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of 660 
natriuresis. Kidney Int 89, 524-526 661 
 662 
 663 
 664 
  665 
 33 
OUTSTANDING QUESTIONS BOX 666 
 667 
- What are the main pathway/s that link insulin action, mitochondrial function and UPR? 668 
- What are the mitochondrial-driven mechanisms that predispose towards faster kidney 669 
disease progression in diabetes? Is there an alteration in the mitochondria driven UPR-670 
mediated response towards cell survival or is it a primary alteration in UPR response?  671 
- Does AMPK, with its important role as a regulator of nutrient utilisation and mitochondrial 672 
function, represent a real answer to diabetes mediated ER-stress mitochondria 673 
dysfunction, UPR, and, if so, what are the mechanisms? 674 
- Could targeting the glycocalyx be a new therapeutic approach for diabetic nephropathy? 675 
What are the important molecular signals from the podocyte and endothelium which 676 
regulate the glycocalyx? 677 
- How does SGLT2 inhibition confer reno-protection? Is it about SGLT2-driven sodium and 678 
volume loss (systemic effect) or tubuloglomerular feedback and inflammation (intrarenal 679 
effect)? Are these mechanisms behind the renoprotective effects of these drugs? 680 
 681 
TRENDS BOX: 682 
- Insulin resistance is a key mechanism for diabetic glomerulopathy. 683 
- Disruption in the molecular communication between glomerular podocytes and endothelia 684 
is critical in the progression of diabetic nephropathy. 685 
- Raised (but not too elevated) mitochondrial superoxide cellular levels in parallel with 686 
healthy mitochondria are protective against progression of diabetic kidney disease. 687 
- A reduction in maximal mitochondrial respiration and reserve capacity could represent an 688 
important driving force for kidney disease progression in diabetes. 689 
- Inhibition of SGLT2-mediated sodium-coupled glucose transport confers renoprotection of 690 
similar magnitude of inhibitors of the renin-angiotensin-aldosterone system. 691 
 692 
 693 
